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Abstract 
In the human pre-B cell line Reh, activation of the cyclic AMP signal transduction pathway induces a rapid, transient lo-fold down-regulation 
of steady-state c-myc mRNA. We have investigated the mechanisms involved in this CAMP-mediated regulation of c-myc expression. Forskolin did 
not alter c-myc mRNA stability. Initiation of c-myc transcripts was strongly inhibited after 1 h of forskolin treatment, as measured by nuclear un-on 
assays. Reinitiation of c-myc transcription was apparent after 3-4 h, and full transcriptional elongation was detected after 8 h of forskolin treatment. 
These data suggest hat cyclic AMP downregulates c-myc expression by inhibition of transcriptional initiation. 
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1. Introduction 
Cyclic AMP functions as a negative regulator of pro- 
liferation in a variety of cell types including lymphoid 
cells [14]. We have previously shown that activation of 
the CAMP signal transduction pathway by forskolin re- 
sults in a strong G1 arrest in the human B-precursor cell 
line Reh [3,5,6]. Concurrent with the growth arrest, the 
steady-state level of c-myc mRNA is transiently down- 
regulated IO-fold between 1 and 4 h and returns to con- 
trol levels within 24 h after forskolin treatment [3,7]. 
The c-myc proto-oncogene is a nuclear phosphopro- 
tein, the function of which is not yet fully understood. 
Extensive evidence suggests important roles for c-myc as 
a regulator in cell proliferation and cell differentiation 
(reviewed in [S]). Recent studies suggest that c-myc func- 
tions as a transcriptional regulator [9-l 11, although tar- 
get genes for c-myc action have yet to be defined. Many 
studies support the notion that tight regulatory control 
of c-myc expression is required for normal cell function 
(discussion in [8]). c-myc gene expression has been shown 
to be regulated by mechanisms acting at the levels of 
transcriptional initiation, transcriptional elongation, and 
mRNA stability (for reviews see [8,12]). 
At present, the exact mechanism for how the CAMP 
signal transduction pathway down-regulates c-myc gene 
expression is poorly understood. Several studies have 
reported that the CAMP analog dibutyryl-CAMP reduces 
the steady-state level of c-myc mRNA during HL-60 
differentiation [13-l 51. Schwartz and co-workers have 
shown that treatment with PGE,, cholera toxin and iso- 
proterenol all reduce the level of c-myc mRNA in GM- 
CSF treated HL60 cells [16]. In fibroblasts, forskolin 
down-regulates the c-myc message and inhibits PDGF- 
induced proliferation [17]. In none of these studies was 
the mechanism for CAMP-dependent reduction investi- 
gated in sufficient detail. This study was initiated to gain 
more insight into the mechanism(s) for CAMP-mediated 
regulation of steady-state c-myc mRNA expression at the 
molecular level. We report here that the level of c-myc 
mRNA is transiently down-regulated by a CAMP-in- 
duced block in initiation of transcription, rather than by 
a transcriptional elongation block mechanism. 
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2. Materials and methods 
2.1. Cells 
The human precursor B cell line Reh (derived from an acute lym- 
phoblastic leukaemia) [18] was kindly provided by M.F. Greaves (Im- 
perial Cancer Research Fund Laboratories, London). Cells were main- 
tained as described [6]. Cells were treated with 100 PM forskolin (Cal- 
biochem) where indicated in the text. 
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2.2. RNA isolation 
Total RNA was isolated from cultures of 20-50 x lo6 cells by the 
guanidine isothiocyanate/CsCl gradient purification [19] or by the LiCV 
urea method [20]. 
2.3. Northern analysis 
Twenty pug of total RNA was size-fractionated in 1% agarose/2.2 M
formaldehvde els and transferred to BIOTRANS nylon filters (ICN 
Biomedicais Inc., USA) or to Hybond N filters (Amersham). Blotswere 
hybridized with “P-labeled human genomic -myc exon 3 [21], chicken 
/I-actin [22] or human glyceraldehyde-3-phosphate d hydropnase 
(GAPDH) [23] cDNA fragments (lo6 cpm/ml) in solution containing 
50% formamide, 5 x SSC, 5 x Denhardt’s, 50 mM sodium phosphate, 
pH 6.5,0.1% SDS and 250 pug/ml sonicated salmon sperm DNA. Blots 
were washed to a strineencv of 0.1 x SSC. 0.1% SDS at 50°C and 
subjected to autoradiograph; at -7O’C using Amersham MP films and 
intensifying screens. 
2.4. mRNA stability 
The stability of c-myc mRNA was measured as the rate of RNA 
degradation inihe presence of RNA synthesis inhibitors. Actinomycin 
D (Boehrineerj or DRB (5’.6-Dichloro-l-n-ribofuranosvl-Benimi- 
dazble, CalGobhem) were u’&l at 10 ,@ml or 0.1 mM, respectively. 
Cells were pre-treated with forskolin for 1 h, after which Actinomycin 
D or DRB was added to block RNA synthesis. Cells were subse- 
quenctly harvested after appropriate time points. Total RNA was ex- 
tracted and subjected to Northern analysis (20,@lane). An additional 
series of total RNA from forskolin treated cells (3O@lane) was loaded 
on the gel due to low levels of the c-myc message. Suitably exposed 
autoradiograms were scanned with a Molecular Dynamics laser den- 
sitometer,~and analyzed by Imagequant (TM) software. The levels of 
c-WC and GAPDH mRNA were calculated relative to controls. Den- 
sitometric scanning analysis hould be interpreted in light of their semi- 
quantative nature. 
2.5. RNase protection assay 
Experiments were conducted essentially as described elsewhere [24]. 
A uniformly [“P]UTP-labeled antisense myc 1 exon RNA transcript 
was generated from a c-myc exon 1 XhoI-PvuII fragment subcloned 
into Bluescript KS- (Stratagene Inc., USA) using T7 polymerase 
(Epicentre Technologies Inc., USA). Fivepg total RNA from Reh cells, 
or 5 pg control tRNA, were hybridized with the antisense RNA tran- 
script (5 x 105-1 x lo6 cpm). Digestion and electrophoresis in 4% 
pol;ac&amide/7.7 M urea gels were done exactly ai described [24]. 
0X174 HaeIII fraements were 3’-labeled with p*PlddATP using a 3 
labeling kit (Ameriham) and run as standards-in ‘the gel. Au&ad& 
ography was performed as described above. 
2.6. Nuclear run-on transcription assay 
Experiments were performed generally as described [25]. Nuclei were 
prepared by mild lysis with NP40 as follows: 20 x lo6 cells per timepoint 
were washed in PBS, and pelleted at 500 x g for 5 min. The cell pellet 
was resuspended in 450 ~1 hypotonic buffer (10 mM Tris- HCl, pH 7.6, 
10 mM NaCl, 3 mM MgCl,). NP4O was added to O.OS%, the tubes were 
immediately mixed by inversion and centrifuged at 200 x g for 5 min. 
Nuclei were carefully resuspended in 90 ~1 glycerol buffer [25]. Tran- 
scription buffer [25] with 220 PCi [“P]UTP (800 Cilmmol) was added, 
and elongation of nascent ranscripts allowed to proceed for 35 min at 
30°C. Elongation was stopped by addition of 50 @(50 U) DNase RQ 
(Promega Biotech) for 1 h. The nuclei were lysed and digested with 200 
~1 of proteinase K solution (3&@) proteinase K (Boehringer), 20 mM 
Tris-HCl, pH 7.5, 50 mM EDTA, 1% SDS) for 30 min at 50°C. Yeast 
tRNA (250 pug) was added and the labeled RNA was purified by phenol/ 
chloroform extraction, precipitated twice with 10 M NH,Ac and 96% 
ethanol at room temperature, washed in ice-cold 70% ethanol and 
resuspended in H20. Filter strips with appropriate probes (10 pg per 
slot. see below) were nre-hybridized in 50% formamide, 20 mM sodium 
phosphate, pi 6.5, 1-M NaCl, 1% SDS, 1 x Denhardt’s, lO@/ml yeast 
tRNA, 50 &ml heparin (Nova Nordisk, Denmark), for 4 h. Equal 
amounts of denatured labeled nascent RNA, typically 5-10 x lo6 Cer- 
enkov units, were added to each filter strip and hybridization proceeded 
for 3648 h at 42°C. The filters were washed twice in 2 x SSC, 0.1% 
SDS for 10 min at 65”C, once in 2 x SSC (subsequent washes at room 
temperature), once in 2 x SSC with 10 &ml RNase A for 30 min and 
2-3 brief washes in 2 x SSC. Autoradiography was done by standard 
procedures at -70°C. 
2.6.1. Filter preparation 
Linearized plasmid probes were denatured at 95°C for 10 min, and 
immediately cooled on ice. An equal volume of ice-cold 20 x SSC was 
added, and the probes were applied to a Hybond N filter (Amersham) 
with the aid of a slot blot manifold (Schleicher & Schuell Minifold II), 
and crosslinked to the filters by UV light. 
2.6.2. Probes 
The following human c-~yc genomic fragments were transferred into 
Bluescript KS- to ensure ai identical hyb;dization background from 
the vector: exon 1 (XhoI-PvuII: 446 bn of mvclPsS 1261): exon 2 (SacI- 
SacI; 1,533 bp of genomic c-&c clone [27])fexon 3’(&-Bcfl; &9 bp 
fragment of pMC41-RC [21]). Chicken /?-actin cDNA (PstI-PstI; 1.2 
kb from pA1 [22]) was ligated into Bluescript KS-. 
3. Results 
To examine whether c-myc mRNA was down-regu- 
lated by a decrease in mRNA stability, we measured the 
mRNA degradation rate after addition of RNA synthe- 
sis inhibitors in control and forskolin-treated cells. Reh 
cells were pretreated with 100 ,uM forskolin for 1 h. 
Actinomycin D was added to a final concentration of 10 
&ml (sufficient for complete inhibition of transcrip- 
tional activity), and RNA was isolated from control and 
forskolin-treated cells after 0, 20, 40 and 60 min and 
subjected to Northern analysis as shown in Fig. 1A. The 
amount of c-myc and GAPDH mRNA at each timepoint 
was plotted relative to the levels of specific message at 
the time of addition of Actinomycin D (0 timepoint) (Fig. 
1B). Fig. 1 shows that c-myc mRNA stability was not 
dramatically decreased by forskolin treatment. Similar 
effects on c-myc mRNA stability were obtained using 
5’,6-Dichloro-1-D-ribofuranosyl-benimidazole (DRB) 
instead of Actinomycin D, or 8-(4-chlorophenylthio)- 
adenosine 3’: S-cyclic monophosphate (8-cpt CAMP) in- 
stead of forskolin (data not shown). Relative to control 
cells, the steady-state c-myc mRNA level in forskolin 
treated cells was reduced to 40% within 1 h (Fig. lA, 
lanes 1 and 5) and to 10% after 34 h [3]. Assessment of 
mRNA stability after treatment with forskolin for longer 
than one hour was therefore not possible, due to the 
rapid decline of the c-myc message. 
Nuclear run-on experiments were performed to deter- 
mine whether c-myc was down-regulated at the level of 
transcriptional initiation or elongation. The kinetics of 
regulation of steady-state c-myc mRNA and #Lactin 
mRNAs by forskolin is shown in a Northern blot in Fig. 
2A for comparison with the nuclear run-on data. Nuclei 
were isolated for in vitro elongation of RNA transcripts 
from control cells and from cells treated with 100 ,uM 
forskolin for 1, 4 or 8 h. In our hands, Reh cell nuclei 
were unusually fragile in NP40 lysis buffer, and the pro- 
cedure for preparation of nuclei was therefore modified 
(see Section 2). We observed a IO-fold increase in 
[32P]UTP incorporation when nuclei were prepared ac- 
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Fig. 1. Analysis ofc-myc RNA stability. (A) Actinomycin D (10 pa/ml) was added to control cells (-) and cells pretreated with 100 ,uM forskolin 
for 1 h (+). Cells were removed after 0, 20,40 and 60 min (as indicated at the top), total RNA was extracted by the guanidine isothiocyanateKsC1 
method and subjected to Northern analysis as described in Section 2. 20 pg total RNA was loaded in each lane. The blot was hybridized with a 
32P-labeled c-myc exon 3 probe (upper panel), stripped and rehybridixed with a 32P-labeled GAPDH probe (lower panel) as indicated. The mobility 
of ribosomal 28s and 18s RNAs are indicated. (B) Suitably exposed autoradiograms of the filters shown in panel (A) were analyzed by laser 
densitometry as described in Section 2. Relative levels of c-myc and GAPDH mRNA were plotted as function of time: c-myc mRNA in control (m) 
and forskolin-treated (0) cells; GAPDH mRNA in control (0) and forskolin-treated (0) cells. 
cording to the described modifications (data not shown). 
The diagram in Fig. 2B shows the positions of the probes 
used for detection of various regions of c-myc tran- 
scripts. Probes a, b and c correspond to exon 1, 2 and 
3, respectively. Within 1 h of forskolin treatment, the 
hybridization signals detected by all three c-myc probes 
were strongly suppressed (Fig. 2C, lanes 1 and 2), sug- 
gesting a block in transcriptional initiation. No elevated 
exon Hexon 2 signal ratio typical of an elongation block 
was observed, even when the signal ratio was adjusted 
for the difference in the number of incorporated UTPs 
detected by the exon 1 and exon 2 probes. This result 
suggests that the CAMP signal transduction pathway 
down-regulates c-myc expression by inhibiting initiation 
of c-myc transcripts. 
We also investigated the kinetics of c-myc RNA re- 
expression at the transcriptional evel. Transcriptional 
activity was measured by nuclear run-on experiments 
with nuclei from cells treated with forskolin for 4 or 
8 h (Fig. 2C). After 4 h, initiation of nascent RNA tran- 
script was evident (exon 1 probe), and after 8 h, c-myc 
transcriptional elongation proceeded as in control cells 
(Fig. 2C, lanes 1 and 4). The timepoint for reinitiation 
of c-myc transcription was determined in more detail 
with cells treated with 100 ,uM forskolin for 1, 2, and 
3 h. The resulting autoradiogram (Fig. 2D) shows that 
reinitiation of c-myc transcription in exon 1 was not 
detected before 3 h of forskolin treatment. We did not 
observe a pronounced increase in the nascent exon l/ 
exon 2 transcript ratio, which would suggest a transcrip- 
tional elongation block mechanism acting concurrent 
with reinitiation of c-myc transcription, This possibility 
can not be excluded, however, as a slight increase in the 
exon Vexon 2 signal ratio in nuclei from cells treated 
with forskolin for 3 and 4 h is reproducibly detected (Fig. 
2C,D). The difference in exposure times of the autoradi- 
ography films (2 and 7 days, respectively) accounts for 
the apparent discrepancies between hybridization signals 
in Fig. 2 parts C and D. We conclude that c-myc tran- 
scription is reinitiated between 3 and 4 h and that full 
transcriptional activity is restored after 8 h of forskolin 
treatment. 
Differential promoter usage has been described as an 
important mechanism for induction of a transcriptional 
elongation block in the c-myc gene [12]. The ratio of 
transcripts initiated from the Pl and P2 promotors has 
been shown to correlate with regulation of transcrip- 
tional read-through at the distal end of c-myc exon 1 [ 121. 
We examined the trancriptional usage of c-myc promo- 
tors Pl and P2 by RNase protection assay. An exon 1 
antisense XhoI-PvuII probe distinguishes between Pl 
(445 nt) and P2 (350 nt) derived c-myc transcripts (see 
diagram in Fig. 3B). This probe does not distinguish 
between PO- and Pl-derived transcripts, but mRNA 
transcribed from the PO promoter is usually less than 5% 
of total c-myc mRNA [12]. Fig. 3A shows that c-myc 
P2-derived transcripts are initiated at a Pl/P2 ratio of I:2 
to 1:3 in Reh cells (Fig. 3A, lane C) in accordance with 
previous data for lymphoid cells [28,29]. Furthermore, 
the Pl/P2 transcript ratio was unaltered by forskolin 
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Fig. 2. Nuclear run-on analysis of c-myc transcription. (A) Total RNA was isolated by the LiCYurea method from control cells (C) or cells treated 
with 100,~M forskolin for 4,8,24 or 48 h, respectively, and subjected to Northern analysis (5,@lane) as described in Section 2. Filters were hybridized 
with 32P-labeled c-myc exon 3 ClaI-EcoRI or /I-actin plasmid probes and subjected to autoradiography as described. Positions of c-myc and /?-actin 
are indicated to the right. (B) Diagram of the 8 kb human c-myc gene (drawn to scale). Relevant probes and restriction sites are indicated: a, exon 
1 XhoI-PvuII; b, exon 2 SacI-SacI; c, exon 3 ClaI-BgZI. Restriction sites are: H, HindIII; E, EcoRI; P, &I; Pv, PvuII; S, SacI; C, ClaI and B, BcK 
(C) Nuclear run-on analysis of c-myc transcriptional activity in control and forskolin-treated cells. Nuclei were prepared from 30 x lo6 control (C) 
Reh cells or cells treated with 100 ,uM forskolin for 1, 4 or 8 h. c-myc probes for exons 1, 2 and 3 are indicated in panel (B) as probes a, b and c, 
respectively. A chicken /J-actin cDNA fragment in Bluescript KS- was used as control (B-actin) together with the empty vector Bluescript KS- (BS). 
Nuclear run-on experiments were performed as described, and detailed descriptions of the probes are given in Section 2. The autoradiograms are 
exposed for 2 days. Autoradiograms presented are representative for three experiments. (D) Nuclear run-on analysis of transcriptional activity of 
c-myc at 1, 2 and 3 h after forskolin addition. Nuclear run-on assay was performed as in (B), except that Reh cells were stimulated with 100 PM 
forskolin for 1, 2 and 3 h as indicated. Probes and other conditions were as in panel (B). The autoradiogram was exposed for 1 week. 
treatment (Fig. 3A, lane F) supporting the nuclear run- 
on data in the notion that c-myc transcription is not 
down-regulated by the CAMP signal transduction path- 
way through a transcriptional elongation block mecha- 
nism. 
4. Discussion 
The c-myc gene is one of the few examples of genes 
(other than genes coding for components of the CAMP 
signal transduction pathway itself) that are negatively 
regulated at the transcriptional level by CAMP. Few 
studies have examined the effects of CAMP on the regu- 
lation of c-myc at the molecular level. The present study 
extends current data on transcriptional regulation of c- 
myc by CAMP In the human B-precursor cell line Reh, 
we have shown that inhibition of c-myc transcript initia- 
tion occurs early (< 1 h) after forskolin treatment. Re- 
initiation of c-myc transcription is observed after 3- 4 h 
and full transcriptional readthrough of the c-myc gene is 
restored after 8 h. Furthermore, we have shown that 
CAMP does not affect c-myc mRNA stability. Our results 
are generally in agreement with a recent report from 
Rock and colleagues that dibutyryl-CAMP down- regu- 
lated c-myc mRNA after 6 h by inhibition of transcrip- 
tional initiation in a murine CSF-1 dependent macro- 
phage cell line, BACl.2F5 [30], although our study de- 
tects a much earlier inhibitory effect on c-myc transcrip- 
tional initiation. 
It can not be excluded that forskolin exerts its effects 
through other mechanisms than the CAMP signal 
transduction pathway (see discussion in [31]). However, 
the generally accepted view is that the major target for 
forskolin is activation of adenylate cyclase with subse- 
quent activation of CAMP-dependent protein kinase 
(cAK). Transient downregulation of c-myc mRNA in 
Reh cells and similar inhibitory effects on cell growth 
were obtained also with the CAMP analog %bromo- 
CAMP (unpublished observations). We have also re- 
cently transfected regulatory and catalytic subunits of 
cAK into Reh cells, and showed that enhanced levels of 
human Ca catalytic subunit potentiated the growth in- 
hibitory effects of CAMP (Task&, K., Andersson, K.B., 
Erikstein, B.K., Hansson, V., Jahnsen, T., and Blom- 
hoff, H.K., submitted for publication). It is therefore 
unlikely that effects observed in our cell system are due 
to other effects of forskolin than activation of adenylate 
cyclase with subsequent action of CAMP-dependent pro- 
tein kinase and downstream effecters. 
The best studied mechanism for rapid transcriptional 
control of c-myc expression is the transcriptional elon- 
gation block (or attenuation) mechanism. Originally 
identified in differentiating HL60 cells [32], successive 
studies have shown that this elongation blockage mech- 
anism is a common regulatory feature in several cell 
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Fig. 3. RNase protection analysis of c-myc promoter usage in Reh cells. 
(A) Total RNA (5 pg) isolated from control Reh cells, or cells treated 
with 100 PM forskolin for 4 h, was hybridized to a “P-labeled c-myc 
exon 1 (XhoI-PvuII) antisense probe. RNase protection assays were 
performed as described in Section 2. Lanes C, control cells; F, 4 h/ 
forskolin treatment; R, Probe hybridized with 5 pg tRNA, P: non- 
digested probe; M, 3’-labeled 0X174 HaeIII fragments. The size of the 
0X174 fragments are indicated to the right. Positions of undigested 
probe, Pl and P2 derived transcripts are indicated to the left. (B) 
Diagram of the relevant portion of the human c-myc gene showing the 
probe used for RNase protection assays in (A). Size of in vitro tran- 
scribed antisense probe (slanted rectangle) and expected protected frag- 
ments (open rectangles) are indicated. The size of in vitro transcribed 
probe includes the linker regions from the vector. The probe protects 
two fragments of 444 and 348 nt. which are derived from transcripts 
initiated at the Pl and P2 promoters, respectively. For restriction en- 
zyme abbreviations, see legend to Fig. 2B. 
systems (reviewed in [S]). In resting peripheral blood T 
lymphocytes, mitogens increase c-myc mRNA synthesis 
by a protein synthesis-dependent release from a tran- 
scriptional elongation block [33]. In Reh cells, cyclo- 
heximide delays the re-expression of c-myc mRNA after 
forskolin treatment (HKB, unpublished observations), 
suggesting that short-lived proteins are also required for 
75 
renewed c-myc mRNA synthesis. The requirement for 
protein synthesis in reinitiation of c-myc transcription in 
Reh cells is paralleled by the release of the elongation 
block in T cells. In contrast to the T cell study however, 
our analysis of promotor usage and the nuclear run-on 
data in Reh cells supports the conclusion that renewal of 
c-myc RNA synthesis is due to transcript reinitiation 
rather than release from an elongation block. 
TGF/3 is the only other reported agent in addition to 
inducers or agonists of CAMP, that induces a similar 
transient down-regulatory effect on c-myc mRNA by 
blocking c-myc transcriptional initiation (< 1 h) in 
BALB/MK keratinocytes [34]. The CAMP and TGF/? 
signal transduction pathways that regulate c-myc expres- 
sion by regulating transcriptional initiation activity, may 
define a separate major pathway for regulation of c-myc 
expression, distinct from signal inducers that regulate 
transcriptional attenuation. 
Despite efforts from many groups in defining the exact 
mechanisms for regulating transcriptional initiation of 
the c-myc gene, this question is not resolved. However, 
several &acting elements in the promoters of the c-myc 
gene itself have recently been identified (discussed in [S]). 
Several studies provide evidence for the involvement of 
both the retinoblastoma gene product pRb and the tran- 
scription factor E2F in regulation of c-myc gene expres- 
sion [34,35]. Both the E2F element 5’ to the P2 promoter 
and the TGFB responsive element (TCE) 5’ to the Pl 
promoter have been shown to confer repression of tran- 
script initiation in the c-myc promoter by overexpression 
of pRb. Since the c-myc promoter does not contain con- 
ventional CAMP-responsive elements, we have tested 
both c-myc Pl (189 bp) and P2 (165 bp) promoter frag- 
ments, and oligonucleotides for the TCE and E2F ele- 
ments in electrophoretic mobility shift assays. We were 
unable to detect any changes in proteins binding to any 
of these elements in nuclear extracts from cells treated 
with forskolin for various time periods (K.B.A., data not 
shown). We speculate that a non-prototype CAMP-t-e- 
sponsive element may lie at a greater distance from the 
c-myc promoter, or that CAMP-mediated events may af- 
fect other interactions than the DNA-binding properties 
of protein complexes binding to the c-myc promoter. 
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